Enhancement of anti-inflammatory drug activity by multivalent adamantane-based dendrons

Biomaterials

Volumn 33, Issue 22, 2012, Pages 5610-5617

  Lamanna, Giuseppe ^a   Russier, Julie ^a   Dumortier, Hélène ^a   Bianco, Alberto ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adamantane; Anti inflammatory activity; Dendrons; Drug delivery; Ibuprofen

Indexed keywords

ADAMANTANES; ANTI-INFLAMMATORY ACTIVITY; ANTI-INFLAMMATORY DRUGS; BIOLOGICAL INTERACTIONS; DENDRONS; IBUPROFEN; IN-VITRO; MULTIVALENCY; MULTIVALENCY EFFECTS; STRAIGHT-FORWARD METHOD; THERAPEUTIC APPLICATION;

DRUG DELIVERY;

DENDRIMERS;

ADAMANTANE; DENDRIMER; IBUPROFEN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL SURVIVAL; DENDRIMERS; DRUG SYNERGISM; IBUPROFEN; MACROPHAGES; MICE;

EID: 84861220812     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.072     Document Type: Article

References (41)

1. Newkome G.R., Shreiner C. Dendrimers derived from 1 → 3 branching motifs. Chem Rev 2010, 110:6338-6442.
2. Mintzer M.A., Grinstaff M.W. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 2011, 40:173-190.
3. Medina S.H., El-Sayed M.E. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009, 109:3141-3157.
4. Dufès C., Uchegbu I.F., Schätzlein A.G. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005, 57:2177-2202.
5. Quanming L., Guohua J., Kangkang T. Dendrimers in drug-delivery applications. Design Monom Polym 2010, 13:301-324.
6. Lee C.C., MacKay J.A., Fréchet J.M.J., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
7. Boas U., Heegaard P.M. Dendrimers in drug research. Chem Soc Rev 2004, 33:43-63.
8. Turnbull W.B., Stoddart J.F. Design and synthesis of glycodendrimers. Rev Mol Biotechnol 2002, 90:231-255.
9. Ehrlich P.H. The effect of multivalency on the specificity of protein and cell interactions. J Theor Biol 1979, 81:123-127.
10. Autumn K., Liang Y.A., Hsieh S.T., Zesch W., Chan W.P., Kenny T.W., et al. Adhesive force of a single gecko foot-hair. Nature 2000, 405:681-685.
11. Mammen M., Choi S.K., Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998, 37:2754-2794.
12. Cecioni S., Faure S., Darbost U., Bonnamour I., Parrot-Lopez H., Roy O., et al. Selectivity among two lectins: probing the effect of topology, multivalency and flexibility of " clicked" multivalent glycoclusters. Chem Eur J 2011, 17:2146-2159.
13. Decroocq C., Rodríguez-Lucena D., Russo V., Mena Barragán T., Ortiz Mellet C., Compain P. The multivalent effect in glycosidase inhibition: probing the influence of architectural parameters with cyclodextrin-based iminosugar click clusters. Chem Eur J 2011, 17:13825-13831.
14. Lundquist J.J., Debenham S.D., Toone E.J. Multivalency effects in protein-carbohydrate interaction: the binding of the Shiga-like toxin 1 binding subunit to multivalent C-linked glycopeptides. J Org Chem 2000, 65:8245-8250.
15. Lamanna G., Russier J., Ménard-Moyon C., Bianco A. HYDRAmers: design, synthesis and characterization of different generation novel Hydra-like dendrons based on multifunctionalized adamantane. Chem Commun 2011, 47:8955-8957.
16. Pavet V., Beyrath J., Pardin C., Morizot A., Lechner M.C., Briand J.P., et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 2010, 70:1101-1110.
17. Humblet V., Misra P., Bhushan K.R., Nasr K., Ko Y.S., Tsukamoto T., et al. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem 2009, 52:544-550.
18. Bosnjakovic A., Mishra M.K., Ren W., Kurtoglu Y.E., Shi T., Fan D., et al. Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation. Nanomedicine: NBM 2011, 7:284-294.
19. Mishra M.K., Kotta K., Hali M., Wykes S., Gerard H.C., Hudson A.P., et al. PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine: NBM 2011, 7:935-944.
20. Chowdhury B., Roy D., Chavan U., Mukhopadhyay S. The anti-inflammatory, antipyretic, analgesic compound ibuprofen also has antibacterial activity against Gram-positive bacteria. Med Sci Res 1996, 24:801-802.
21. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
22. Williams K.I., Higgs G.A. Eicosanoids and inflammation. J Pathol 1988, 156:101-110.
23. Portanova J.P., Zhang Y., Anderson G.D., Hauser S.D., Masferrer J.L., Seibert K., et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996, 184:883-891.
24. Bailly S., Ferrua B., Fay M., Gougerot-Pocidalo M.A. Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP. Cytokine 1990, 2:205-210.
25. Komatsu H., Yaju H., Chiba K., Okumoto T. Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells. Int J Immunopharmacol 1991, 13:1137-1146.
26. Angst M.S., Clark J.D., Carvalho B., Tingle M., Schmelz M., Yeomans D.C. Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: a microdialysis study. Pain 2008, 139:15-27.
27. Lang F., Robert J.M., Boucrot P., Welin L., Petit J.Y. New antiinflammatory compounds that inhibit tumor necrosis factor production: probable interaction with protein kinase C activation. J Pharmacol Exp Ther 1995, 275:171-176.
28. Lin H.I., Chu S.J., Wang D., Feng N.H. Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect 2004, 37:8-15.
29. Martich G.D., Danner R.L., Ceska M., Suffredini A.F. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991, 173:1021-1024.
30. Sironi M., Gadina M., Kankova M., Riganti F., Mantovani A., Zandalasini M., et al. Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. Int J Immunopharmacol 1992, 14:1045-1050.
31. Lee Y.J., Chuang Y.C. Ibuprofen augments pro-inflammatory cytokine release in a mouse model of Vibrio vulnificus infection. Microbiol Immunol 2010, 54:542-550.
32. Endres S., Whitaker R.E., Ghorbani R., Meydani S.N., Dinarello C.A. Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo. Immunology 1996, 87:264-270.
33. Rome L.H., Lands W.E. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975, 72:4863-4865.
34. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
35. Grilli M., Pizzi M., Memo M., Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 1996, 274:1383-1385.
36. Stuhlmeier K.M., Li H., Kao J.J. Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol 1999, 57:313-320.
37. Wulczyn F.G., Krappmann D., Scheidereit C. The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. J Mol Med 1996, 74:749-769.
38. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071.
39. Fujiwara N., Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:281-286.
40. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
41. Stack W.A., Mann S.D., Roy A.J., Heath P., Sopwith M., Freeman J., et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997, 349:521-524.